The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients
Abstract
Target hematocrit/hemoglobin values in dialysis patients are still controversial. The Spanish Cooperative Renal Patients Quality of Life Study Group (including 34 hemodialysis units) conducted a prospective, 6-mo study of the effect on patient functional status and quality of life of using epoetin to achieve normal hematocrit in hemodialysis patients with anemia. The possible adverse effects of increased hematocrit, patient hospitalization, and epoetin requirements were also studied. The study included 156 patients (age range, 18 to 65 yr). Given the minimal experience in the safety of increasing hematocrit in dialysis patients to normal levels with epoetin, stable patients on hemodialysis who had received epoetin treatment for at least 3 mo and had a stable hemoglobin level of > or = 9 g/dl were included in the study. Patients with antecedents of congestive cardiac failure, ischemic cardiopathy, diabetes mellitus, uncontrolled hypertension, cerebrovascular accident or seizures, malfunction of the vascular access or severe comorbidity (defined by a comorbidity index), and those over 65 yr of age were excluded from the study. Quality of life was measured with the Sickness Impact Profile (SIP) and Karnofsky scale. Patients completed questionnaires at home at onset and conclusion of the 6-mo study. Mean hematocrit increased from 30.9 to 38.4% and hemoglobin from 10.2 to 12.5 g/dl during the study. Health indicator scores improved significantly: mean Physical Dimension (SIP) from 5.38 to 4.1 (P < 0.005); mean Psychosocial Dimension from 9.2 to 7 (P < 0.001); mean global SIP from 8.9 to 7.25 (P < 0.001); mean Karnofsky scale score from 75.6 to 78.4 (P < 0.01). (SIP is scaled so that lower scores represent better functional status, and vice versa for the Karnofsky scale). Therefore, functional status and quality of life improved with increased hematocrit. No deaths occurred. Three patients (2%) were censored for hypertension and nine (5.7%) for thrombosis of the vascular access. The cumulative probability of thrombosis of the vascular access was 0.067. The average epoetin dose rose from 93 +/- 62 U/kg per wk at onset to 141 +/- 80 U/kg per wk at conclusion, a 51% increase. The number of patients hospitalized decreased and hospital lengths of stay were shorter during the study period than in the same patients in the 6-mo period preceding the study (P < 0.05). Nine patients (5.7%) had thrombosis of the vascular access. There were no changes in the prevalence of arterial hypertension, but three patients (2%) showed hypertension that was difficult to control. It is concluded that normalization of hematocrit in selected hemodialysis patients, i.e., nondiabetic patients without severe cardiovascular or cerebrovascular comorbidities, improves quality of life and decreases morbidity without significant adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
The Sickness Impact Profile: Development and Final Revision of a Health Status Measure
Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. (1981) · Medical Care · doi:10.1097/00005650-198108000-00001 · Cited by 4,619
The clinical evaluation of chemotherapeutic agents in cancer
Karnofsky, D. A. (1949) · Medical Entomology and Zoology · Cited by 2,933
Evaluation of Chemotherapeutic Agents.
(1950) · Archives of Internal Medicine · doi:10.1001/archinte.1950.00230180176018 · Cited by 1,133
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90130-4 · Cited by 769
Hematocrit Level and Associated Mortality in Hemodialysis Patients
MA, J. Z., EBBEN, J., XIA, H., & COLLINS, A. J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103610 · Cited by 577
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 406
Daugirdas, J. T., Blake, P. G., & Ing, T. S. (1994) · Cited by 401
Performance status assessment in cancer patients
Conill, C., Verger, E., & Salamero, M. (1990) · Cancer · doi:10.1002/1097-0142(19900415)65:8<1864::aid-cncr2820650832>3.0.co;2-u · Cited by 361
Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis
Kaufman, J. S., Reda, D. J., Fye, C. L., Goldfarb, D. S., Henderson, W. G., Kleinman, J. G., & Vaamonde, C. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390902 · Cited by 300
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Quality of life in end-stage renal disease patients
Valderrábano, F., Jofre, R., & López-Gómez, J. M. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.26824 · Cited by 558
Self-citationLocatelli, F., Pisoni, R. L., Combe, C., Bommer, J., Andreucci, V. E., Piera, L., Greenwood, R., Feldman, H. I., Port, F. K., & Held, P. J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg458 · Cited by 468
Pisoni, R. L., Bragg-Gresham, J. L., Young, E. W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J. M., Kerr, P. G., Mendelssohn, D. C., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.023 · Cited by 391
Metadata
- Authors
- MORENO, F., SANZ-GUAJARDO, D., LÓPEZ-GÓMEZ, J. M., JOFRE, R., & VALDERRÁBANO, F.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2000-02
- Volume
- 11
- Issue
- 2
- Pages
- 335-342
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2108582978
- Cited by
- 254
- References
- 22
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients. https://app.cochat.ai/papers/10.1681/asn.v112335
- The paper
- MORENO, F., SANZ-GUAJARDO, D., LÓPEZ-GÓMEZ, J. M., JOFRE, R., & VALDERRÁBANO, F. (2000). Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v112335
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.